| Literature DB >> 25043047 |
Paul A Northcott1, Catherine Lee2, Thomas Zichner3, Adrian M Stütz4, Serap Erkek5, Daisuke Kawauchi6, David J H Shih7, Volker Hovestadt8, Marc Zapatka8, Dominik Sturm6, David T W Jones6, Marcel Kool6, Marc Remke7, Florence M G Cavalli7, Scott Zuyderduyn9, Gary D Bader9, Scott VandenBerg10, Lourdes Adriana Esparza11, Marina Ryzhova12, Wei Wang8, Andrea Wittmann6, Sebastian Stark6, Laura Sieber6, Huriye Seker-Cin6, Linda Linke6, Fabian Kratochwil6, Natalie Jäger13, Ivo Buchhalter13, Charles D Imbusch14, Gideon Zipprich14, Benjamin Raeder4, Sabine Schmidt15, Nicolle Diessl15, Stephan Wolf15, Stefan Wiemann15, Benedikt Brors13, Chris Lawerenz14, Jürgen Eils14, Hans-Jörg Warnatz16, Thomas Risch16, Marie-Laure Yaspo16, Ursula D Weber8, Cynthia C Bartholomae17, Christof von Kalle18, Eszter Turányi19, Peter Hauser20, Emma Sanden21, Anna Darabi21, Peter Siesjö21, Jaroslav Sterba22, Karel Zitterbart22, David Sumerauer23, Peter van Sluis24, Rogier Versteeg24, Richard Volckmann24, Jan Koster24, Martin U Schuhmann25, Martin Ebinger25, H Leighton Grimes26, Giles W Robinson27, Amar Gajjar28, Martin Mynarek29, Katja von Hoff29, Stefan Rutkowski29, Torsten Pietsch30, Wolfram Scheurlen31, Jörg Felsberg32, Guido Reifenberger32, Andreas E Kulozik33, Andreas von Deimling34, Olaf Witt33, Roland Eils35, Richard J Gilbertson27, Andrey Korshunov34, Michael D Taylor36, Peter Lichter37, Jan O Korbel38, Robert J Wechsler-Reya11, Stefan M Pfister39.
Abstract
Medulloblastoma is a highly malignant paediatric brain tumour currently treated with a combination of surgery, radiation and chemotherapy, posing a considerable burden of toxicity to the developing child. Genomics has illuminated the extensive intertumoral heterogeneity of medulloblastoma, identifying four distinct molecular subgroups. Group 3 and group 4 subgroup medulloblastomas account for most paediatric cases; yet, oncogenic drivers for these subtypes remain largely unidentified. Here we describe a series of prevalent, highly disparate genomic structural variants, restricted to groups 3 and 4, resulting in specific and mutually exclusive activation of the growth factor independent 1 family proto-oncogenes, GFI1 and GFI1B. Somatic structural variants juxtapose GFI1 or GFI1B coding sequences proximal to active enhancer elements, including super-enhancers, instigating oncogenic activity. Our results, supported by evidence from mouse models, identify GFI1 and GFI1B as prominent medulloblastoma oncogenes and implicate 'enhancer hijacking' as an efficient mechanism driving oncogene activation in a childhood cancer.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25043047 PMCID: PMC4201514 DOI: 10.1038/nature13379
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962